CytoMed Therapeutics Ltd (NASDAQ: GDTC)’s stock price has gone rise by 20.70 in comparison to its previous close of 2.27, however, the company has experienced a 22.73% increase in its stock price over the last five trading days. globenewswire.com reported 2025-02-06 that SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board of Directors (the “Board”) as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read.
Is It Worth Investing in CytoMed Therapeutics Ltd (NASDAQ: GDTC) Right Now?
Company’s 36-month beta value is -0.25.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GDTC is 4.83M, and currently, short sellers hold a 2.09% ratio of that floaft. The average trading volume of GDTC on April 10, 2025 was 20.01K shares.
GDTC’s Market Performance
The stock of CytoMed Therapeutics Ltd (GDTC) has seen a 22.73% increase in the past week, with a 4.58% rise in the past month, and a -7.43% fall in the past quarter. The volatility ratio for the week is 12.02%, and the volatility levels for the past 30 days are at 9.23% for GDTC. The simple moving average for the past 20 days is 11.34% for GDTC’s stock, with a 21.35% simple moving average for the past 200 days.
GDTC Trading at 4.92% from the 50-Day Moving Average
After a stumble in the market that brought GDTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.34% of loss for the given period.
Volatility was left at 9.23%, however, over the last 30 days, the volatility rate increased by 12.02%, as shares surge +5.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.04% upper at present.
During the last 5 trading sessions, GDTC rose by +22.73%, which changed the moving average for the period of 200-days by +33.01% in comparison to the 20-day moving average, which settled at $2.46. In addition, CytoMed Therapeutics Ltd saw -19.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GDTC starting from mDR Ltd, who proposed sale 86,410 shares at the price of $2.66 back on Mar 24 ’25. After this action, mDR Ltd now owns shares of CytoMed Therapeutics Ltd, valued at $229,850 using the latest closing price.
mDR Ltd, the 10% Owner of CytoMed Therapeutics Ltd, proposed sale 115,400 shares at $2.31 during a trade that took place back on Nov 05 ’24, which means that mDR Ltd is holding shares at $265,997 based on the most recent closing price.
Stock Fundamentals for GDTC
Current profitability levels for the company are sitting at:
- -14.74 for the present operating margin
- 0.25 for the gross margin
The net margin for CytoMed Therapeutics Ltd stands at -11.68. The total capital return value is set at -0.32. Equity return is now at value -26.36, with -24.78 for asset returns.
Based on CytoMed Therapeutics Ltd (GDTC), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -5.77. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -164.11.
Currently, EBITDA for the company is -2.94 million with net debt to EBITDA at 1.55. When we switch over and look at the enterprise to sales, we see a ratio of 163.97. The receivables turnover for the company is 0.57for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.53.
Conclusion
In a nutshell, CytoMed Therapeutics Ltd (GDTC) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
